Pharma & Biotech Global Week in Review 29 June 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Restoril (Temazepam) – US: CAFC: Obviousness of a pharmaceutical formulation: Tyco v. Mutual Pharmaceutical (Patently-O) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

2011 BIO International Convention Preview – Part III (Patent Docs)

Australia: Australia and New Zealand move closer to joint regulation of medicines and medical devices (IP Whiteboard)

APO: No extension for a deliberate decision: Carol Almond-Martin v Novo Nordisk Health Care AG (IP Whiteboard) (Patentology)

Austria: SPC is presumed valid in proceedings for injunctive relief, says top Austrian court (The SPC blog)

Brazil: the case of pharmaceutical patent examination – a dual examination system? (IP tango)

Europe: AG Opinion for C-125/10 – English translation available! Merck & Co Inc v Deutsches Patent- und Markenamt (The SPC blog)

Europe: SPC: waiting for the Court of Justice of the European Union (Kluwer Patent Blog)

India: Roger Bates, pharma patents and contempt of court? (Spicy IP)

Indonesia’s pharma IP problems (IP Komodo)

US: House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support (BIOtechNow) (Patent Baristas)

US: Supreme Court takes two more patent cases: Kappos v Hyatt; Caraco v Novo Nordisk (Patently-O)

US: Patent Profile: Antisense Pharma secures patents for convection enhanced delivery (Patent Docs)

 

Products

Adenoscan (Adenosine) – US: Patent infringement complaint in response to Para IV certification: Astellas US LLC et al. v. Sagent Pharmaceuticals, Inc. et al. (Patent Docs)

Angiomax (Bivalirudin) – US: Efforts to obtain a PTE for ANGIOMAX patent continue as the US House passes an Amendment to the America Invents Act in ‘after business hours’ vote (FDA Law Blog)

Avodart (Dutasteride) – US: Patent infringement complaint in response to Para IV certification: GlaxoSmithKline LLC v. Roxane Laboratories Inc. et al. (Patent Docs)

Azilect (Rasagiline) – US: Patent infringement complaint in response to Para IV certification: Teva Neuroscience, Inc. et al. v. Apotex Inc. et al. (Patent Docs)

Deferacirox – India: Cipla wins pre grant opposition (593/CHENP/2005): Novartis v. Cipla (Spicy IP)

Effexor (Venlafaxine) – US: Intellipharmaceutics announces settlement for its generic version of Effexor (GenericsWeb)

Eloxatin (Oxaliplatin) – US: Patent infringement complaint in response to Para IV certification: Sanofi-Aventis U.S. LLC et al. v. Sun Pharma Global FZE et al. (Patent Docs)

Fortical – US: Challenge to Unigene’s osteoporosis patent, among the reexamination requests for the week of June 20, 2011 (WHDA)

Glucoamyl L 706+ / Glucoamyl LG20 – US: Novozymes files patent infringement suit against Central Trading Enterprises over Glucoamyl L 706+ and Glucoamyl LG20 products (Patent Docs)

Glumetza (Metformin) – US: Patent infringement complaint in response to Para IV certification: Depomed, Inc. et al. v. Sun Pharma Global FZE et al. (Patent Docs)

Lipitor (Atorvastatin) – UK Atorvastatin hearing for 11 July – Warner-Lambert v Teva UK (The SPC Blog)

Metoclopramide – US: Supreme Court issues decision on generic drug pre-emption: To borrow from Harry Caray – “Holy cow! Generics win! Generics win!” PLIVA Inc. v. Mensing; Actavis Elizabeth, L.L.C. v. Mensing; Actavis, Inc. v. Demahy (FDA Law Blog)

Modafinil – UK: EWHC (Pat): Patents not infringed but obvious – Cephalon, Inc v Orchid Europe (EPLAW) (IPKat)

Paracetamol – Nigerian court slaps huge damages on GSK in Panadol dispute (Afro-IP)

Silenor (Doxepin) – US: Somaxon files patent infringement suit against Mylan for trying to market generic Silenor (GenericsWeb)

Suprane (Desfluorane) – US: FDA grants Baxter’s petition for second 30-month stay relating to Suprane (Orange Book Blog)

Tykerb (Lapatinib) – US: Natco joins forces with Lupin to sell generic Tykerb gets orphan status for cancer drug candidate (GenericsWeb)

Restoril (Temazepam) – US: CAFC: Obviousness of a pharmaceutical formulation: Tyco v. Mutual Pharmaceutical (Patently-O) (Patent Docs)

Viagra (Sildenafil) – US: Pfizer fights to keep up Viagra patent (IP Osgoode)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: